Mira Pharmaceuticals Inc(MIRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.38 | Insider Own | 7.92% | Shs Outstand | 42.0M | Perf Week | 10.89% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 38.7M | Perf Month | -6.65% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.03 | Inst Own | 5.79% | Short Float | 0.73% | Perf Quarter | -17.06% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 0.54% | Short Ratio | 0.48 | Perf Half Y | -35.93% |
| Sales | 0.00B | P/B | 3.2 | EPS next 5Y | 32.7% | ROA | -684.27% | Short Interest | 0.28M | Perf YTD | -58.8% |
| Book/sh | 0.19 | P/C | 3.22 | EPS past 3/5Y | -41.42% -211.56% | ROE | -710.85% | 52W High | -63.19% ($1.69) | Perf Year | -57.1% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -380.24% | 52W Low | 21.98% ($0.51) | Perf 3Y | -58.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -186.73% | Gross Margin | - | Volatility(W/M) | 9.07% 9.79% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 200.08 | EPS Q/Q | 68.18% | Profit Margin | - | RSI (14) | 49.35 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 200.08 | Sales Q/Q | - | SMA20 | 4.9% ($0.59) | Beta | 1.59 | Target Price | $6.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -11.7% ($0.7) | Rel Volume | 0.09 | Prev Close | $0.62 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -33.16% ($0.93) | Avg Volume(3M) | 0.59M | Price | $0.62 |
| IPO | 2023/8/3 | Option/Short | No/Yes | Trades | 104 | Volume | 52,550 | Change | 0.19% |
🧠 This is a biopharmaceutical company developing marijuana-like new drugs. Its lead candidate, MIRA-55, is a next-generation painkiller designed to retain marijuana's pain-relieving effects while eliminating hallucinogenic side effects. The company is researching applications for neuropathic pain, anxiety, and early-stage dementia, and has received confirmation from the DEA that it is not a controlled substance.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded less than usual. That is 9% of its average volume.
MIRA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -58.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #19 of 21 in the industry
Based on market cap of $26M.
AMRN#17 Amarin Corp ADR $247M PER - 
NSRX#18 Nasus Pharma Ltd $34M PER - MIRA#19 Mira Pharmaceuticals Inc $26M PER - 
SCLX#20 Scilex Holding Company $11M PER - 
MDCX#21 Medicus Pharma Ltd $3M PER - 
FAQ
What kind of company is MIRA?
MIRA belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of MIRA?
The market cap of MIRA is approximately $26M, ranking 5,105 within its sector.
What is the 52-week high and low for MIRA?
MIRA has recorded a 52-week high of $1.69 and a low of $0.51.
